LifeMD Plunges 27.45% on Earnings Miss, Guidance Cut

On August 6, 2025, LifeMD's stock experienced a significant drop of 27.45% in pre-market trading, reflecting investor concerns over the company's recent financial performance and future outlook.

LifeMD reported a substantial loss for the second quarter of 2025, with earnings and revenue surprises of -200.00% and -6.02%, respectively. Despite a 23% year-over-year increase in revenue to $62.2 million, the company fell short of analyst estimates by approximately $4.1 million. This revenue growth was driven by a 30% increase in telehealth revenue, which reached $48.6 million. However, the company's adjusted EBITDA, while rising 223% to $7.1 million, was not enough to offset the negative sentiment surrounding the earnings miss.

Adding to the negative sentiment, LifeMD revised its full-year 2025 revenue guidance down to $250 million-$255 million, significantly lower than the previous estimate of $270.32 million. The company also cut its adjusted EBITDA view to $27 million-$29 million from the previous range of $31 million-$33 million. This downward revision in guidance, coupled with the earnings miss, has raised concerns about the company's ability to meet future financial targets and maintain its growth trajectory.